BR9609738B1 - dispositivo estabilizado de emplasto para aplicação de uma droga esteróide. - Google Patents

dispositivo estabilizado de emplasto para aplicação de uma droga esteróide.

Info

Publication number
BR9609738B1
BR9609738B1 BRPI9609738-8A BR9609738A BR9609738B1 BR 9609738 B1 BR9609738 B1 BR 9609738B1 BR 9609738 A BR9609738 A BR 9609738A BR 9609738 B1 BR9609738 B1 BR 9609738B1
Authority
BR
Brazil
Prior art keywords
application
steroid drug
plaster device
stabilized
stabilized plaster
Prior art date
Application number
BRPI9609738-8A
Other languages
English (en)
Portuguese (pt)
Other versions
BR9609738A (pt
Inventor
Uday Jain
Sronivasan Venkateshwaran
Charles D Ebert
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BR9609738A publication Critical patent/BR9609738A/pt
Publication of BR9609738B1 publication Critical patent/BR9609738B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI9609738-8A 1995-07-20 1996-06-21 dispositivo estabilizado de emplasto para aplicação de uma droga esteróide. BR9609738B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/504,430 US5780050A (en) 1995-07-20 1995-07-20 Drug delivery compositions for improved stability of steroids
PCT/US1996/010711 WO1997003629A1 (en) 1995-07-20 1996-06-21 Drug delivery compositions for improved stability of steroids

Publications (2)

Publication Number Publication Date
BR9609738A BR9609738A (pt) 1999-03-16
BR9609738B1 true BR9609738B1 (pt) 2009-05-05

Family

ID=24006230

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9609738-8A BR9609738B1 (pt) 1995-07-20 1996-06-21 dispositivo estabilizado de emplasto para aplicação de uma droga esteróide.

Country Status (12)

Country Link
US (1) US5780050A (en:Method)
EP (2) EP2305195B1 (en:Method)
JP (2) JP3422796B2 (en:Method)
KR (1) KR100505171B1 (en:Method)
CN (2) CN100446769C (en:Method)
AU (1) AU710760B2 (en:Method)
BR (1) BR9609738B1 (en:Method)
CA (1) CA2226425C (en:Method)
DK (2) DK0876131T3 (en:Method)
MX (1) MX9800545A (en:Method)
WO (1) WO1997003629A1 (en:Method)
ZA (1) ZA965607B (en:Method)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6024974A (en) * 1995-01-06 2000-02-15 Noven Pharmaceuticals, Inc. Composition and methods for transdermal delivery of acid labile drugs
US5783208A (en) * 1996-07-19 1998-07-21 Theratech, Inc. Transdermal drug delivery matrix for coadministering estradiol and another steroid
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US20060002949A1 (en) 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
DE19724200A1 (de) 1997-06-09 1998-12-10 Basf Ag Bisiminosubstituierte Phenylverbindungen
US20020012694A1 (en) * 1997-09-17 2002-01-31 Alfred J. Moo-Young Transdermal administration of ment
ATE418988T1 (de) * 1997-11-10 2009-01-15 Strakan Int Ltd Penetrationsfördernde und irritationsvermindernde systeme mit testosteron
US6210705B1 (en) 1997-12-15 2001-04-03 Noven Pharmaceuticals, Nc. Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
US20020102291A1 (en) * 1997-12-15 2002-08-01 Noven Pharmaceuticals, Inc. Compositions and method for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
GB9803032D0 (en) * 1998-02-12 1998-04-08 Ethical Pharmaceuticals Uk Lim Transdermal delivery devices
EP0943333A1 (de) * 1998-03-18 1999-09-22 S.W. Patentverwertungs GmbH Medikament zur Prophylaxe und/oder Behandlung des Mammakarzinoms enthaltend einen Hemmer der Bildung von Oestrogenen
JP2002523195A (ja) 1998-08-31 2002-07-30 ジョンソン・アンド・ジョンソン・コンシューマー・カンパニーズ・インコーポレイテッド ブレードを備える電子輸送装置
AU4188100A (en) * 1999-04-08 2000-11-14 Gregory M. Glenn Dry formulation for transcutaneous immunization
CA2370349C (en) 1999-04-16 2013-01-29 Johnson & Johnson Consumer Companies, Inc. Electrotransport delivery system comprising internal sensors
WO2000064528A1 (en) 1999-04-28 2000-11-02 Situs Corporation Drug delivery system
US7074747B1 (en) 1999-07-01 2006-07-11 Johnson & Johnson Consumer Companies, Inc. Cleansing compositions
US6762158B2 (en) 1999-07-01 2004-07-13 Johnson & Johnson Consumer Companies, Inc. Personal care compositions comprising liquid ester mixtures
WO2001001949A1 (en) 1999-07-01 2001-01-11 Johnson And Johnson Consumer Companies, Inc. Cleansing compositions
US6890553B1 (en) 1999-07-08 2005-05-10 Johnson & Johnson Consumer Companies, Inc. Exothermic topical delivery device
DE60033935T2 (de) 1999-07-08 2007-11-29 Johnson & Johnson Consumer Companies, Inc. Exothermes oberflächliches zuführungsgerät
US7384650B2 (en) * 1999-11-24 2008-06-10 Agile Therapeutics, Inc. Skin permeation enhancement composition for transdermal hormone delivery system
EP1132084A1 (en) * 2000-03-06 2001-09-12 Docteur Nature Srl Transdermal device for the slow release of soybean derived vegetable estrogens
USRE44145E1 (en) 2000-07-07 2013-04-09 A.V. Topchiev Institute Of Petrochemical Synthesis Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties
CA2415076C (en) 2000-07-07 2010-04-13 Mikhail M. Feldstein Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
WO2002045701A2 (en) * 2000-12-05 2002-06-13 Noven Pharmaceuticals, Inc. Crystallization inhibition of drugs in transdermal drug delivery systems
ATE398461T1 (de) 2001-02-13 2008-07-15 Us Gov Sec Army Impstoffe zur transkutanen immunisierung gegen reisediarrhö
EP1381381A1 (en) * 2001-03-19 2004-01-21 Gregory M. Glenn Patch for transcutaneous immunization
US8840918B2 (en) 2001-05-01 2014-09-23 A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences Hydrogel compositions for tooth whitening
US8541021B2 (en) 2001-05-01 2013-09-24 A.V. Topchiev Institute Of Petrochemical Synthesis Hydrogel compositions demonstrating phase separation on contact with aqueous media
US8206738B2 (en) 2001-05-01 2012-06-26 Corium International, Inc. Hydrogel compositions with an erodible backing member
US20050113510A1 (en) 2001-05-01 2005-05-26 Feldstein Mikhail M. Method of preparing polymeric adhesive compositions utilizing the mechanism of interaction between the polymer components
CA2445086C (en) 2001-05-01 2008-04-08 A.V. Topchiev Institute Of Petrochemical Synthesis Hydrogel compositions
US20050215727A1 (en) 2001-05-01 2005-09-29 Corium Water-absorbent adhesive compositions and associated methods of manufacture and use
WO2002087642A2 (en) 2001-05-01 2002-11-07 A.V. Topchiev Institute Of Petrochemical Synthesis Two-phase, water-absorbent bioadhesive composition
CA2451043C (en) * 2001-06-18 2011-02-15 Noven Pharmaceuticals, Inc. Enhanced drug delivery in transdermal systems
DE10141650C1 (de) * 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
US20030175329A1 (en) * 2001-10-04 2003-09-18 Cellegy Pharmaceuticals, Inc. Semisolid topical hormonal compositions and methods for treatment
US7921999B1 (en) * 2001-12-20 2011-04-12 Watson Laboratories, Inc. Peelable pouch for transdermal patch and method for packaging
US20040137004A1 (en) * 2002-03-19 2004-07-15 Glenn Gregory M Patch for transcutaneous immunization
EA009024B1 (ru) 2002-06-25 2007-10-26 АКРУКС ДиДиЭс ПиТиУай ЭлТиДи Фармацевтическая композиция для чрескожной доставки активного агента (варианты)
DE10305811A1 (de) * 2003-02-12 2004-08-26 Ethicon Gmbh Chirurgisches Implantat
ES2933479T3 (es) * 2003-09-29 2023-02-09 Novo Nordisk Healthcare Ag Estabilidad mejorada de formulaciones de progestágenos
DK1670440T3 (da) * 2003-09-29 2014-07-07 Novo Nordisk As HRT formuleringer
AU2005210637B2 (en) 2004-01-30 2010-09-16 A.V. Topchiev Institute Of Petrochemical Synthesis Rapidly dissolving film for delivery of an active agent
CN103497713B (zh) 2004-08-05 2018-07-17 考里安国际公司 粘合剂组合物
DE102004059880A1 (de) * 2004-12-10 2006-06-14 Grünenthal GmbH Stabiles, hormonhaltiges (Zwischen-)Produkt
ES2607454T3 (es) 2005-06-03 2017-03-31 Acrux Dds Pty Ltd Método y composición para el suministro transdérmico de testosterona
US20070065494A1 (en) * 2005-08-03 2007-03-22 Watson Laboratories, Inc. Formulations and Methods for Enhancing the Transdermal Penetration of a Drug
US10137135B2 (en) * 2005-08-15 2018-11-27 Allergan Sales, Llc Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith
NZ567056A (en) 2005-10-12 2012-02-24 Unimed Pharmaceuticals Llc Improved testosterone gel and method of use
US20070259029A1 (en) * 2006-05-08 2007-11-08 Mcentire Edward Enns Water-dispersible patch containing an active agent for dermal delivery
US20070258935A1 (en) * 2006-05-08 2007-11-08 Mcentire Edward Enns Water dispersible films for delivery of active agents to the epidermis
US20080057090A1 (en) * 2006-09-01 2008-03-06 Mcentire Edward Enns Wrinkle masking film composition for skin
US7879942B2 (en) * 2006-10-05 2011-02-01 Eastman Chemical Company Switchable adhesive article for attachment to skin and method of using the same
MY150763A (en) * 2006-10-24 2014-02-28 Repros Therapeutics Inc Compositions and methods for suppressing endometrial proliferation
WO2008083423A1 (en) 2007-01-11 2008-07-17 Acrux Dds Pty Ltd Spreading implement
US20080175877A1 (en) * 2007-01-22 2008-07-24 Isense Corporation Adhesives with antiperspirant and/or anti-inflammatory additives
EP2664323B1 (en) 2007-04-16 2020-07-29 Corium, Inc. Solvent-cast microneedle arrays containing active
JP4948267B2 (ja) * 2007-05-25 2012-06-06 東芝機械株式会社 シート・フィルム成形装置及びシート・フィルム成形方法
US20090098191A1 (en) * 2007-10-16 2009-04-16 Anderson Christopher G Use of bases to stabilize transdermal formulations
DE102008013701A1 (de) * 2008-03-11 2009-09-17 Lts Lohmann Therapie-Systeme Ag Transdermales Therapeutisches System mit stabilisierter Membran
WO2009142699A1 (en) * 2008-05-19 2009-11-26 The Procter & Gamble Company Treatment of heart failure in women
US8784879B2 (en) 2009-01-14 2014-07-22 Corium International, Inc. Transdermal administration of tamsulosin
CA2798145C (en) 2010-05-04 2022-10-18 Corium International, Inc. Method and device for transdermal delivery of parathyroid hormone using a microprojection array
WO2012103015A2 (en) * 2011-01-27 2012-08-02 Csi Gmbh Extended-release beta agonist/steroid transdermal patches and methods for using the same
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
US9849095B2 (en) * 2011-12-01 2017-12-26 Teikoku Seiyaku Co., Ltd. Ropinirole-containing adhesive patch
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11052231B2 (en) 2012-12-21 2021-07-06 Corium, Inc. Microarray for delivery of therapeutic agent and methods of use
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
AU2014249471B2 (en) 2013-03-12 2019-01-24 Corium Pharma Solutions, Inc. Microprojection applicators
AU2014237357B2 (en) 2013-03-15 2019-11-28 Corium Pharma Solutions, Inc. Multiple impact microprojection applicators and methods of use
BR112015022625B1 (pt) 2013-03-15 2023-01-31 Corium, Inc Aparelho de microestrutura para entrega de agente terapêutico
WO2014150293A1 (en) 2013-03-15 2014-09-25 Corium International, Inc. Microarray with polymer-free microstructures, methods of making, and methods of use
USD750788S1 (en) 2013-11-26 2016-03-01 Acrux Dds Pty Ltd Topical spreading applicator
USD749225S1 (en) 2013-11-26 2016-02-09 Acrux Dds Pty Ltd Topical spreading applicator
WO2015179782A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
KR20170040209A (ko) 2014-07-29 2017-04-12 쎄러퓨틱스엠디, 인코퍼레이티드 경피 크림
WO2016036866A1 (en) 2014-09-04 2016-03-10 Corium International, Inc. Microstructure array, methods of making, and methods of use
US10857093B2 (en) 2015-06-29 2020-12-08 Corium, Inc. Microarray for delivery of therapeutic agent, methods of use, and methods of making
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
CN108996832B (zh) * 2018-08-17 2021-05-07 南宁市黄陈生猪养殖场 一种利用菌剂处理工业废水的工艺
CN108773912B (zh) * 2018-08-17 2021-06-08 南宁市黄陈生猪养殖场 一种畜禽养殖污水的菌剂处理工艺
MX2022005168A (es) 2019-11-06 2022-06-08 Smartech Topical Inc Formulaciones topicas de inhibidores de la ciclooxigenasa y su uso.
CN111067709B (zh) * 2019-11-15 2022-05-13 惠州市浩明科技股份有限公司 医用胶带的制备方法及卷绕储存方法
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3551554A (en) 1968-08-16 1970-12-29 Crown Zellerbach Corp Enhancing tissue penetration of physiologically active agents with dmso
US3711606A (en) 1970-09-02 1973-01-16 Crown Zellerbach Corp Enhancing tissue penetration of physiologically active steroidal agents with dmso
US3711602A (en) 1970-10-30 1973-01-16 Crown Zellerbach Corp Compositions for topical application for enhancing tissue penetration of physiologically active agents with dmso
US3964482A (en) * 1971-05-17 1976-06-22 Alza Corporation Drug delivery device
CA1165240A (en) 1980-07-09 1984-04-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
US4557943A (en) 1983-10-31 1985-12-10 Advanced Semiconductor Materials America, Inc. Metal-silicide deposition using plasma-enhanced chemical vapor deposition
US4954343A (en) * 1986-03-29 1990-09-04 Nitto Electric Industrial Co., Ltd. Dermal pharmaceutical preparations
US5145682A (en) * 1986-05-30 1992-09-08 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for postmenopausal syndrome treatment and process for administration
US4863970A (en) 1986-11-14 1989-09-05 Theratech, Inc. Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols
JPS63132889A (ja) 1986-11-21 1988-06-04 Tanabe Seiyaku Co Ltd キナゾリノン誘導体
US5023084A (en) * 1986-12-29 1991-06-11 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
CH674618A5 (en:Method) * 1987-04-02 1990-06-29 Ciba Geigy Ag
US4983395A (en) * 1987-11-12 1991-01-08 Theratech Inc. Device for administering an active agent to the skin or mucosa
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
AU622162B2 (en) * 1988-04-22 1992-04-02 Ciba-Geigy Ag Transdermal monolith systems
US4829224A (en) 1988-05-23 1989-05-09 George Gandelman Battery pack for cellular telephone
US5059426A (en) * 1989-03-22 1991-10-22 Cygnus Therapeutic Systems Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
US5232703A (en) * 1989-07-21 1993-08-03 Izhak Blank Estradiol compositions and methods for topical application
JP2718433B2 (ja) 1989-09-08 1998-02-25 シグナス インコーポレイテッド 経皮ドラッグデリバリーのための固体マトリックスシステム
US5252334A (en) * 1989-09-08 1993-10-12 Cygnus Therapeutic Systems Solid matrix system for transdermal drug delivery
JP2849937B2 (ja) * 1990-04-18 1999-01-27 日東電工株式会社 医療用貼付剤
NZ240358A (en) * 1990-10-29 1994-09-27 Alza Corp Transdermal contraceptive device comprising (as active agents) an estrogen and a gestodene together with a skin permeation enhancer
US5122383A (en) * 1991-05-17 1992-06-16 Theratech, Inc. Sorbitan esters as skin permeation enhancers
US5152997A (en) * 1990-12-11 1992-10-06 Theratech, Inc. Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels
JPH04342532A (ja) * 1991-05-21 1992-11-30 Sekisui Chem Co Ltd 経皮吸収貼付剤
IL116539A (en) * 1995-01-06 2002-02-10 Noven Pharma Preparations given through the skin of unstable anti-acid drugs
JP4032532B2 (ja) * 1998-10-23 2008-01-16 日立化成工業株式会社 回路部材の実装方法

Also Published As

Publication number Publication date
KR19990028496A (ko) 1999-04-15
DK2305195T3 (en) 2015-06-29
HK1017983A1 (en) 1999-12-10
CN1191475A (zh) 1998-08-26
CN1137689C (zh) 2004-02-11
AU6287496A (en) 1997-02-18
CN1509718A (zh) 2004-07-07
JPH10510548A (ja) 1998-10-13
BR9609738A (pt) 1999-03-16
CA2226425C (en) 2009-08-18
EP0876131A4 (en:Method) 1998-12-02
KR100505171B1 (ko) 2005-11-22
DK0876131T3 (da) 2014-11-24
US5780050A (en) 1998-07-14
EP0876131A1 (en) 1998-11-11
CA2226425A1 (en) 1997-02-06
MX9800545A (es) 1998-04-30
EP2305195A1 (en) 2011-04-06
AU710760B2 (en) 1999-09-30
CN100446769C (zh) 2008-12-31
WO1997003629A1 (en) 1997-02-06
ZA965607B (en) 1997-03-19
EP0876131B1 (en) 2014-08-13
JP4344076B2 (ja) 2009-10-14
EP2305195B1 (en) 2015-04-22
HK1066724A1 (zh) 2005-04-01
JP3422796B2 (ja) 2003-06-30
JP2001072580A (ja) 2001-03-21

Similar Documents

Publication Publication Date Title
BR9609738B1 (pt) dispositivo estabilizado de emplasto para aplicação de uma droga esteróide.
IT233201Y1 (it) Dispositivo a due componenti per la somministrazione di farmaci
BR9701673A (pt) Disposição para a aplicação de um líquido medicinal
EE9700241A (et) Farmatseutiline kompositsioon transdermaalseks manustamiseks
PT1153626E (pt) Aparelho de administracao de medicamentos
PT1221919E (pt) Dispositivo para a distribuicao de uma droga oftalmica
PT812195E (pt) Composicao farmaceutica para compostos de piperidinoalcanol
EE04006B1 (et) Transkorneaalne seade ravimite kontrollitavaks manustamiseks
FI973243L (fi) Uusi farmaseuttinen yhdistelmä
ID19755A (id) Komposisi untuk pemberian transdermal obat-obat steroid
NO973630D0 (no) System for regulert avgivelse av medikament
NO961136D0 (no) Farmasöytisk formuleringsgrunnlag for nano-suspensjoner
NO962606L (no) Farmasöytisk sammensetning
FI963984L (fi) Uusi oraalinen farmaseuttinen annostelumuoto
NO975321D0 (no) Farmasöytisk emulsjon omfattende fluorforbindelser
NO981008D0 (no) Farmasöytisk formulering
BR9602021A (pt) Disposição para movimento gradativo de um dispositivo operante
BR9609327A (pt) Novos derivados de oxazolidinona processos para sua preparação e agentes farmacêuticos que contêm estes compostos
BR9607095A (pt) Composto composição farmacêutica e processos para fabricar e para administrar um composto
BR9600665A (pt) Dispositivo para estabilizar uma folha de material
PT783310E (pt) Novos medicamentos hormonais e sua utilizacao para a correccao de carencias estrogenicas
BR9804947A (pt) Modifica-Æo de cristal de um agente farmac-utico
FI973229A7 (fi) Uusi farmaseuttinen koostumus
LV11727A (lv) Farmaceitiska kompozicija
NO20000811D0 (no) Fremgangsmåte for valg av medicament

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: WATSON LABORATORIES, INC. - UTAH (US)

Free format text: ALTERADO DE: THERATECH, INC.

B25D Requested change of name of applicant approved

Owner name: WATSON LABORATORIES, INC. (US)

Free format text: ALTERADO DE: WATSON LABORATORIES, INC. - UTAH

B25A Requested transfer of rights approved

Owner name: WATSON PHARMACEUTICALS, INC. (US)

Free format text: TRANSFERIDO DE: WATSON LABORATORIES, INC.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 28/07/2009, OBSERVADAS AS CONDICOES LEGAIS.

B24C Patent annual fee: request for for restoration

Free format text: REFERENTE AS 15A E 16A ANUIDADES.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE AO DESPACHO 24.3 PUBLICADO NA RPI 2188 DE 11/12/2012.